Cagrilintide + Semaglutide: Is the Combo 'Better,' and for Which Plateau Pattern?

Weight-loss plateaus on semaglutide are one of the most frustrating experiences in the GLP-1 medication journey. You've been losing steadily, the medication has been working, and then—nothing. The scale stalls for weeks or months, and you start wondering: would adding cagrilintide break through this? The question of whether combining cagrilintide with semaglutide is better than semaglutide alone is more nuanced than a simple yes or no, and understanding the different types of plateaus matters for knowing whether dual therapy—or a different strategy entirely—is the right next step.

The CagriSema Clinical Trial Results: What We Know So Far

Novo Nordisk's REDEFINE clinical trial program has provided the strongest evidence for the semaglutide-cagrilintide combination:

• Mean weight loss of ~22.7% at 68 weeks with CagriSema, compared to ~15.8% with semaglutide 2.4 mg alone.
• More participants achieved ≥20% weight loss with the combination than with either agent individually.
• The combination appeared to maintain efficacy over the full study period, with the weight-loss curve continuing to trend downward at 68 weeks for many participants.
• GI side effects were manageable with appropriate titration, though rates of nausea and vomiting were somewhat higher than semaglutide alone.

These are genuinely impressive results. But "better on average" doesn't necessarily mean "better for you," especially when the question is specifically about breaking through a plateau.

Why People Plateau on Semaglutide Alone

Not all plateaus are the same. Understanding yours is the first step to solving it:

The Metabolic Adaptation Plateau

As you lose weight, your body requires fewer calories. Your resting metabolic rate decreases, and adaptive thermogenesis can reduce energy expenditure beyond what weight loss alone would predict. This is the most common plateau—your caloric deficit has simply narrowed to the point where weight loss stalls.

The Appetite Return Plateau

Some people experience a gradual return of hunger and cravings after months on semaglutide, even at maximum doses. This may reflect partial receptor desensitization or the body's counter-regulatory responses to sustained weight loss. Food noise comes back, portions creep up, and the medication feels less effective.

The Behavioral Drift Plateau

This one is sneaky. After months of medication-assisted appetite suppression, eating patterns can gradually shift—more calorie-dense food choices, more frequent snacking, or fewer high-fiber and protein-rich foods. The medication is still working, but behavioral changes have offset its effect.

The Body Composition Plateau

If you've been exercising (especially resistance training), you may be gaining muscle while losing fat. The scale stalls, but body composition is actually improving. This isn't a true plateau—it's progress that the scale can't capture.

How Adding an Amylin Analog Might Help—For Specific Plateau Types

Cagrilintide works on amylin receptors, which modulate appetite through different brain pathways than GLP-1 receptors. Here's where this distinction becomes practically important:

For the Appetite Return Plateau: Potentially Helpful

If your plateau is driven by returning hunger despite maximum-dose semaglutide, adding a second agent that targets a different satiety pathway could meaningfully restore appetite suppression. This is the scenario where the "additive" nature of dual-pathway therapy makes the most pharmacological sense.

For the Metabolic Adaptation Plateau: Maybe, But Not a First-Line Strategy

Adding cagrilintide might further reduce food intake, re-establishing a caloric deficit. But it's addressing the problem indirectly. Strategies like increasing protein intake, adding resistance training, or adjusting meal timing might achieve the same result without adding a second medication.

For the Behavioral Drift Plateau: Probably Not the Right Solution

If the issue is food choices rather than hunger, adding another appetite suppressant doesn't address the root cause. A nutrition-focused approach—including adequate fiber intake and protein optimization—is likely more appropriate.

For the Body Composition Plateau: Definitely Not the Right Solution

If you're recomposing (gaining muscle, losing fat), you don't need more appetite suppression—you need patience and better metrics than the scale.

Alternative Plateau-Breaking Strategies Worth Trying First

Before jumping to combination pharmacotherapy, clinicians often recommend optimizing what you're already doing:

Protein Optimization

Many people on GLP-1 medications struggle to hit adequate protein targets because their overall intake has dropped. Aim for 1.2–1.6 g per kg of body weight daily. Protein preserves lean mass, has a higher thermic effect than carbohydrates or fat, and supports satiety through mechanisms that complement GLP-1 activity.

Fiber Intake

Adequate fiber supports gut health, promotes satiety through mechanical stretch receptors in the stomach, and feeds beneficial gut bacteria that produce short-chain fatty acids involved in appetite regulation. Many people on semaglutide consume far less fiber than recommended because they're simply eating less of everything. A fiber supplement like Psyllium MD PhD Formulated can help bridge this gap without adding significant calories.

Activity Adjustments

If you've been doing primarily cardio, adding or increasing resistance training can counteract metabolic adaptation by preserving or building metabolically active tissue. Even modest increases in muscle mass can meaningfully affect resting metabolic rate.

Meal Timing and Composition

Some people find that restructuring when and how they eat—front-loading protein, spacing meals differently, or adjusting around their injection day—can restart progress without any medication changes.

The Case for Clinical Evaluation Before Adding Medications

Here's the bottom line: adding cagrilintide to semaglutide is a significant decision that should be based on a clear diagnosis of why you've plateaued, not just that you've plateaued.

An obesity-medicine specialist can help you:

• Identify which type of plateau you're experiencing
• Determine whether nutritional, behavioral, or pharmacological intervention is most appropriate
• Evaluate whether you're a candidate for combination therapy based on your medical history
• Design a titration protocol if dual therapy is indicated
• Monitor for side effects and adjust the plan based on your response

The GLP-1 Clinical Program at Casa de Santé specializes in exactly this kind of evaluation—helping you understand whether your plateau requires a medication adjustment, a nutrition overhaul, or a combination of both. Rather than guessing whether adding cagrilintide is the answer, a clinician can help you make a data-informed decision.

And if optimizing your fiber and protein intake is part of the plan (which it usually is, regardless of medication decisions), the Psyllium MD PhD Formulated supplement was designed specifically to support the nutritional needs of people on GLP-1 medications.

This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before making changes to your treatment plan.